This company has been acquired
Reunion Neuroscience Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Reunion Neuroscience's earnings have been declining at an average annual rate of -68.5%, while the Biotechs industry saw earnings growing at 30% annually. Revenues have been growing at an average rate of 83.9% per year.
Información clave
-68.5%
Tasa de crecimiento de los beneficios
-4.6%
Tasa de crecimiento del BPA
Crecimiento de la industria Biotechs | 51.1% |
Tasa de crecimiento de los ingresos | 83.9% |
Rentabilidad financiera | -178.9% |
Margen neto | n/a |
Última actualización de beneficios | 31 Mar 2023 |
Actualizaciones de resultados anteriores recientes
Desglose de ingresos y gastosBeta
Cómo gana y gasta dinero Reunion Neuroscience. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
---|---|---|---|---|
31 Mar 23 | 0 | -38 | 13 | 13 |
31 Dec 22 | 5 | -74 | 39 | 11 |
30 Sep 22 | 5 | -68 | 40 | 9 |
30 Jun 22 | 5 | -57 | 39 | 9 |
31 Mar 22 | 0 | -18 | 11 | 7 |
31 Dec 21 | 1 | -20 | 13 | 6 |
30 Sep 21 | 1 | -22 | 13 | 5 |
30 Jun 21 | 1 | -24 | 13 | 4 |
31 Mar 21 | 1 | -23 | 13 | 4 |
31 Dec 20 | 0 | -16 | 9 | 3 |
30 Sep 20 | 0 | -9 | 6 | 2 |
30 Jun 20 | 0 | -5 | 4 | 1 |
31 Mar 20 | 0 | -3 | 3 | 0 |
Ingresos de calidad: REUN is currently unprofitable.
Margen de beneficios creciente: REUN is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: Insufficient data to determine if REUN's year-on-year earnings growth rate was positive over the past 5 years.
Acelerando crecimiento: Unable to compare REUN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: REUN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.6%).
Rentabilidad financiera
Alta ROE: REUN has a negative Return on Equity (-178.92%), as it is currently unprofitable.